

Food and Drug Administration

[Docket No. 95M-0397]

Progressive Angioplasty Systems, Inc.; Premarket Approval of the PAS Lacrosse™ PTCA Catheter**AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Progressive Angioplasty Systems, Inc., Menlo Park, CA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the PAS LaCrosse™ PTCA Catheter. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of September 27, 1995, of the approval of the application.

DATES: Petitions for administrative review by January 18, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Veronica Price, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8243.

SUPPLEMENTARY INFORMATION: On April 4, 1994, Progressive Angioplasty Systems, Inc., Menlo Park, CA 94025-1516, submitted to CDRH an application for premarket approval of the PAS LaCrosse™ PTCA Catheter. The device is a percutaneous transluminal coronary angioplasty (PTCA) dilatation catheter and it is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.

In accordance with the provisions of section 515(c)(2) of the act (21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of 1990, this premarket approval application (PMA) was not referred to the Circulatory System Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, for review and recommendation because the information in the PMA substantially duplicated information previously reviewed by this panel. On September 27, 1995, CDRH approved the application by a letter to the applicant

from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before January 18, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: December 4, 1995.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 95-30743 Filed 12-18-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95M-0393]

Bioetica, Inc.; Premarket Approval of HEMOSTAGENE® Absorbable Collagen Hemostatic Sponge**AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Bioetica, Inc., Westbrook, ME, on behalf of Coletica, S. A., Lyon, France, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of HEMOSTAGENE® Absorbable Collagen Hemostatic Sponge. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of August 15, 1995, of the approval of the application.

DATES: Petitions for administrative review by January 18, 1996.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Frances M. Curtis, Center for Devices and Radiological Health (HFZ-410), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-3090.

SUPPLEMENTARY INFORMATION: On August 30, 1993, the U.S. representative, Bioetica, Inc., Westbrook, ME 04092, on behalf of Coletica, S. A., Lyon, France, submitted to CDRH an application for premarket approval of HEMOSTAGENE® Absorbable Collagen Hemostatic Sponge. The device is an absorbable hemostatic agent and is indicated for use in surgical procedures (other than in neurosurgical, ophthalmic, and urological) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

In accordance with the provisions of section 515(c)(2) of the act (21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act of 1990, this premarket approval application (PMA) was not referred to the General and Plastic Surgery Devices Panel of the

Medical Devices Advisory Committee, an FDA advisory committee, for review and recommendation because the information in the PMA substantially duplicates information previously reviewed by this panel.

On August 15, 1995, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before January 18, 1996, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated

to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: November 29, 1995.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 95-30697 Filed 12-18-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95M-0398]

Cochlear Corp.; Premarket Approval of New Indication for Use for the Nucleus 22-Channel Cochlear Implant

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the supplemental application by Cochlear Corp., Englewood, CO, for premarket approval, under section 515 of the Federal Food, Drug, and Cosmetic Act (the act), of a new indication for use for the Nucleus 22-Channel Cochlear Implant. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of August 21, 1995, of the approval of the application.

DATES: Petitions for administrative review by January 18, 1996.

ADDRESSES: Address written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Marilyn Flack, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2080.

SUPPLEMENTARY INFORMATION: On August 8, 1992, Cochlear Corp., Englewood, CO 80112, submitted to CDRH a supplemental application for premarket approval of an expanded indication for use for the Nucleus 22-Channel Cochlear Implant. The device was originally approved in 1985 for use in adults who demonstrated postlinguistic, bilateral, sensorineural hearing loss and obtained little or no benefit from conventional amplification. It was approved in 1990 for use in children who demonstrated bilateral, profound, sensorineural hearing loss and obtained little or no benefit from conventional amplification or vibrotactile hearing aids. The expanded indication for use

now includes patients, 18 years and older, who have bilateral, postlinguistic, sensorineural hearing impairment and obtain limited benefit from appropriate binaural hearing aids. Limited benefit from amplification is defined by test scores of 30 percent correct or less in the best-aided listening condition on tape-recorded tests of open-set sentence recognition. These patients typically have low frequency residual hearing in the moderate-to-profound range and profound (greater than or equal to 90 dBHL) hearing loss in the mid-to-high speech frequencies.

On April 20, 1995, the Ear, Nose and Throat Devices Advisory Panel, an FDA advisory panel, reviewed and recommended approval of the supplemental application.

On August 21, 1995, CDRH approved the supplemental application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act (21 U.S.C. 360e(g)), for administrative review of CDRH's decision to approve this supplemental application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the supplemental application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and